{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T01:30:50Z","timestamp":1782869450884,"version":"3.54.5"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,22]]},"DOI":"10.7759\/cureus.50948","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T14:12:16Z","timestamp":1703254336000},"source":"Crossref","is-referenced-by-count":12,"title":["Neuroprotective Potential of Melatonin: Evaluating Therapeutic Efficacy in Alzheimer's and Parkinson's Diseases"],"prefix":"10.7759","author":[{"given":"Norris C","family":"Talbot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M","family":"Luther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah J","family":"Spillers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda  R","family":"Ragland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan J","family":"Kidder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rucha  A","family":"Kelkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahab","family":"Ahmadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Shekoohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X14666161228122115","article-title":"Melatonin: pharmacology, functions and therapeutic benefits","volume":"15","author":"Tordjman S","year":"2017","unstructured":"Tordjman S, Chokron S, Delorme R, Charrier A, Bellissant E, Jaafari N, Fougerou C. Melatonin: pharmacology, functions and therapeutic benefits. Curr Neuropharmacol. 2017, 15:434-43. 10.2174\/1570159X14666161228122115","journal-title":"Curr Neuropharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-007-6529-9","article-title":"Sleep and sleep disturbances: biological basis and clinical implications","volume":"64","author":"Zisapel N","year":"2007","unstructured":"Zisapel N. Sleep and sleep disturbances: biological basis and clinical implications. Cell Mol Life Sci. 2007, 64:1174-86. 10.1007\/s00018-007-6529-9","journal-title":"Cell Mol Life Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-020-00959-7","article-title":"The treatment of sleep dysfunction in neurodegenerative disorders","volume":"18","author":"Voysey ZJ","year":"2021","unstructured":"Voysey ZJ, Barker RA, Lazar AS. The treatment of sleep dysfunction in neurodegenerative disorders. Neurotherapeutics. 2021, 18:202-16. 10.1007\/s13311-020-00959-7","journal-title":"Neurotherapeutics"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2023.05.014","article-title":"Risk of neurodegenerative diseases in patients with sleep disorders: a nationwide population-based case-control study","volume":"107","author":"Lin W","year":"2023","unstructured":"Lin W, Lin YK, Yang FC, et al.. Risk of neurodegenerative diseases in patients with sleep disorders: a nationwide population-based case-control study. Sleep Med. 2023, 107:289-99. 10.1016\/j.sleep.2023.05.014","journal-title":"Sleep Med"},{"key":"ref5","article-title":"Melatonin - The Hormone of Darkness and Its Therapeutic Potential and Perspectives","author":"Vlachou M","year":"2020","unstructured":"Vlachou M. Melatonin - The Hormone of Darkness and Its Therapeutic Potential and Perspectives. IntechOpen, London (ENG); 2020."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00788-6","article-title":"Melatonin levels in the Alzheimer's disease continuum: a systematic review","volume":"13","author":"Nous A","year":"2021","unstructured":"Nous A, Engelborghs S, Smolders I. Melatonin levels in the Alzheimer's disease continuum: a systematic review. Alzheimers Res Ther. 2021, 13:52. 10.1186\/s13195-021-00788-6","journal-title":"Alzheimers Res Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2013.6239","article-title":"Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease","volume":"71","author":"Videnovic A","year":"2014","unstructured":"Videnovic A, Noble C, Reid KJ, et al.. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. JAMA Neurol. 2014, 71:463-9. 10.1001\/jamaneurol.2013.6239","journal-title":"JAMA Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.308071","article-title":"Sleep disorders in Alzheimer's disease: the predictive roles and potential mechanisms","volume":"16","author":"Kuang H","year":"2021","unstructured":"Kuang H, Zhu YG, Zhou ZF, Yang MW, Hong FF, Yang SL. Sleep disorders in Alzheimer's disease: the predictive roles and potential mechanisms. Neural Regen Res. 2021, 16:1965-72. 10.4103\/1673-5374.308071","journal-title":"Neural Regen Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/1748-7161-2-6","article-title":"Melatonin the \"light of night\" in human biology and adolescent idiopathic scoliosis","volume":"2","author":"Grivas TB","year":"2007","unstructured":"Grivas TB, Savvidou OD. Melatonin the \"light of night\" in human biology and adolescent idiopathic scoliosis. Scoliosis. 2007, 2:6. 10.1186\/1748-7161-2-6","journal-title":"Scoliosis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1356.028","article-title":"Mechanisms regulating melatonin synthesis in the mammalian pineal organ","volume":"1057","author":"Schomerus C","year":"2005","unstructured":"Schomerus C, Korf HW. Mechanisms regulating melatonin synthesis in the mammalian pineal organ. Ann N Y Acad Sci. 2005, 1057:372-83. 10.1196\/annals.1356.028","journal-title":"Ann N Y Acad Sci"},{"key":"ref11","unstructured":"Melatonin. (2023). Accessed. June 13, 2023: https:\/\/en.wikipedia.org\/wiki\/Melatonin."},{"key":"ref12","unstructured":"Melatonin Dose. How much should you take?. (2022). Accessed: June 13, 2023: https:\/\/health.clevelandclinic.org\/melatonin-how-much-should-i-take-for-a-good-nights-rest\/."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-016-0052-2","article-title":"Pharmacokinetics of oral and intravenous melatonin in healthy volunteers","volume":"17","author":"Andersen LP","year":"2016","unstructured":"Andersen LP, Werner MU, Rosenkilde MM, Harps\u00f8e NG, Fuglsang H, Rosenberg J, G\u00f6genur I. Pharmacokinetics of oral and intravenous melatonin in healthy volunteers. BMC Pharmacol Toxicol. 2016, 17:8. 10.1186\/s40360-016-0052-2","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.002410","article-title":"Metabolism of melatonin by human cytochromes p450","volume":"33","author":"Ma X","year":"2005","unstructured":"Ma X, Idle JR, Krausz KW, Gonzalez FJ. Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005, 33:489-94. 10.1124\/dmd.104.002410","journal-title":"Drug Metab Dispos"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1152\/physiol.00011.2014","article-title":"Melatonin: exceeding expectations","volume":"29","author":"Reiter RJ","year":"2014","unstructured":"Reiter RJ, Tan DX, Galano A. Melatonin: exceeding expectations. Physiology (Bethesda). 2014, 29:325-33. 10.1152\/physiol.00011.2014","journal-title":"Physiology (Bethesda)"},{"key":"ref16","unstructured":"Melatonin. Uses, interactions and mechanism of action. (2022). Accessed: June 13, 2023: https:\/\/go.drugbank.com\/drugs\/DB01065."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2019.07.025","article-title":"Melatonin: a review of its potential functions and effects on neurological diseases","volume":"176","author":"Gunata M","year":"2020","unstructured":"Gunata M, Parlakpinar H, Acet HA. Melatonin: a review of its potential functions and effects on neurological diseases. Rev Neurol (Paris). 2020, 176:148-65. 10.1016\/j.neurol.2019.07.025","journal-title":"Rev Neurol (Paris)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12638","article-title":"2022 Alzheimer's disease facts and figures","volume":"18","year":"2022","unstructured":"2022 Alzheimer's disease facts and figures. Alzheimers Dement. 2022, 18.700-89. 10.1002\/alz.12638","journal-title":"Alzheimers Dement"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25245789","article-title":"Comprehensive review on Alzheimer's disease: causes and treatment","volume":"25","author":"Breijyeh Z","year":"2020","unstructured":"Breijyeh Z, Karaman R. Comprehensive review on Alzheimer's disease: causes and treatment. Molecules. 2020, 25:5789. 10.3390\/molecules25245789","journal-title":"Molecules"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-007-5416-4_14","article-title":"Alzheimer's disease","volume":"65","author":"De-Paula VJ","year":"2012","unstructured":"De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV. Alzheimer's disease. Subcell Biochem. 2012, 65:329-52. 10.1007\/978-94-007-5416-4_14","journal-title":"Subcell Biochem"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1177\/1179573520907397","article-title":"Current and future treatments in Alzheimer disease: an update","volume":"12","author":"Yiannopoulou KG","year":"2020","unstructured":"Yiannopoulou KG, Papageorgiou SG. Current and future treatments in Alzheimer disease: an update. J Cent Nerv Syst Dis. 2020, 12:1179573520907397. 10.1177\/1179573520907397","journal-title":"J Cent Nerv Syst Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01512-w","article-title":"The FDA-approved anti-amyloid-\u03b2 monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials","volume":"28","author":"Wu W","year":"2023","unstructured":"Wu W, Ji Y, Wang Z, et al.. The FDA-approved anti-amyloid-\u03b2 monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials. Eur J Med Res. 2023, 28:544. 10.1186\/s40001-023-01512-w","journal-title":"Eur J Med Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.66871","article-title":"The role of melatonin in the treatment of type 2 diabetes mellitus and Alzheimer's disease","volume":"18","author":"Shen S","year":"2022","unstructured":"Shen S, Liao Q, Wong YK, et al.. The role of melatonin in the treatment of type 2 diabetes mellitus and Alzheimer's disease. Int J Biol Sci. 2022, 18:983-94. 10.7150\/ijbs.66871","journal-title":"Int J Biol Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030833","article-title":"Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages","volume":"88","author":"Wu YH","year":"2003","unstructured":"Wu YH, Feenstra MG, Zhou JN, et al.. Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. J Clin Endocrinol Metab. 2003, 88:5898-906. 10.1210\/jc.2003-030833","journal-title":"J Clin Endocrinol Metab"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-079x.2003.00065.x","article-title":"Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels","volume":"35","author":"Zhou JN","year":"2003","unstructured":"Zhou JN, Liu RY, Kamphorst W, Hofman MA, Swaab DF. Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res. 2003, 35:125-30. 10.1034\/j.1600-079x.2003.00065.x","journal-title":"J Pineal Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/741974","article-title":"Melatonin and its agonist ramelteon in Alzheimer's disease: possible therapeutic value","volume":"2011","author":"Srinivasan V","year":"2010","unstructured":"Srinivasan V, Kaur C, Pandi-Perumal S, Brown GM, Cardinali DP. Melatonin and its agonist ramelteon in Alzheimer's disease: possible therapeutic value. Int J Alzheimers Dis. 2010, 2011:741974. 10.4061\/2011\/741974","journal-title":"Int J Alzheimers Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2023.2214316","article-title":"Pharmacological and non-pharmacological treatment options for sleep disturbances in Alzheimer's disease","volume":"23","author":"Javed B","year":"2023","unstructured":"Javed B, Javed A, Kow CS, Hasan SS. Pharmacological and non-pharmacological treatment options for sleep disturbances in Alzheimer's disease. Expert Rev Neurother. 2023, 23:501-14. 10.1080\/14737175.2023.2214316","journal-title":"Expert Rev Neurother"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2021.04.034","article-title":"Neurocognitive effects of melatonin treatment in healthy adults and individuals with Alzheimer's disease and insomnia: a systematic review and meta-analysis of randomized controlled trials","volume":"127","author":"Sumsuzzman DM","year":"2021","unstructured":"Sumsuzzman DM, Choi J, Jin Y, Hong Y. Neurocognitive effects of melatonin treatment in healthy adults and individuals with Alzheimer's disease and insomnia: a systematic review and meta-analysis of randomized controlled trials. Neurosci Biobehav Rev. 2021, 127:459-73. 10.1016\/j.neubiorev.2021.04.034","journal-title":"Neurosci Biobehav Rev"},{"key":"ref29","article-title":"Parkinson's disease: etiology, neuropathology, and pathogenesis","author":"Kouli A","year":"2018","unstructured":"Kouli A, Torsney KM, Kuan WL. Parkinson's disease: etiology, neuropathology, and pathogenesis. Parkinson's Disease: Pathogenesis and Clinical Aspects. Stoker TB, Greenland JC (ed): Codon Publications, Brisbane (AU); 2018."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia LV","year":"2015","unstructured":"Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015, 386:896-912. 10.1016\/S0140-6736(14)61393-3","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2007.131045","article-title":"Parkinson's disease: clinical features and diagnosis","volume":"79","author":"Jankovic J","year":"2008","unstructured":"Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008, 79:368-76. 10.1136\/jnnp.2007.131045","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/s0896-6273(03)00568-3","article-title":"Parkinson's disease: mechanisms and models","volume":"39","author":"Dauer W","year":"2003","unstructured":"Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron. 2003, 39:889-909. 10.1016\/s0896-6273(03)00568-3","journal-title":"Neuron"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-017-1686-y","article-title":"Epidemiology of Parkinson's disease","volume":"124","author":"Tysnes OB","year":"2017","unstructured":"Tysnes OB, Storstein A. Epidemiology of Parkinson's disease. J Neural Transm (Vienna). 2017, 124:901-5. 10.1007\/s00702-017-1686-y","journal-title":"J Neural Transm (Vienna)"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8619(05)70259-0","article-title":"Epidemiology of Parkinson's disease","volume":"14","author":"Tanner CM","year":"1996","unstructured":"Tanner CM, Goldman SM. Epidemiology of Parkinson's disease. Neurol Clin. 1996, 14:317-35. 10.1016\/S0733-8619(05)70259-0","journal-title":"Neurol Clin"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM2003ra020003","article-title":"Alzheimer's disease and Parkinson's disease","volume":"348","author":"Nussbaum RL","year":"2003","unstructured":"Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med. 2003, 348:1356-64. 10.1056\/NEJM2003ra020003","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.57.9.1679","article-title":"Prevalence, incidence, and mortality of PD: a door-to-door survey in Ilan county, Taiwan","volume":"57","author":"Chen RC","year":"2001","unstructured":"Chen RC, Chang SF, Su CL, et al.. Prevalence, incidence, and mortality of PD: a door-to-door survey in Ilan county, Taiwan. Neurology. 2001, 57:1679-86. 10.1212\/wnl.57.9.1679","journal-title":"Neurology"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3390\/metabo13050668","article-title":"Changes in the secretion of melatonin and selected adipokines during the progression of Parkinson's disease-preliminary studies","volume":"13","author":"Milanowski J","year":"2023","unstructured":"Milanowski J, Kozerawski K, Fal\u0119cka W, et al.. Changes in the secretion of melatonin and selected adipokines during the progression of Parkinson's disease-preliminary studies. Metabolites. 2023, 13:668. 10.3390\/metabo13050668","journal-title":"Metabolites"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.736026","article-title":"Peripheral clock system abnormalities in patients with Parkinson's disease","volume":"13","author":"Li T","year":"2021","unstructured":"Li T, Cheng C, Jia C, et al.. Peripheral clock system abnormalities in patients with Parkinson's disease. Front Aging Neurosci. 2021, 13:736026. 10.3389\/fnagi.2021.736026","journal-title":"Front Aging Neurosci"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13050797","article-title":"Melatonin as a chronobiotic\/cytoprotective agent in REM sleep behavior disorder","volume":"13","author":"Cardinali DP","year":"2023","unstructured":"Cardinali DP, Garay A. Melatonin as a chronobiotic\/cytoprotective agent in REM sleep behavior disorder. Brain Sci. 2023, 13:797. 10.3390\/brainsci13050797","journal-title":"Brain Sci"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-022-06188-4","article-title":"Safety and efficacy of melatonin, clonazepam, and trazodone in patients with Parkinson's disease and sleep disorders: a randomized, double-blind trial","volume":"43","author":"Hadi F","year":"2022","unstructured":"Hadi F, Agah E, Tavanbakhsh S, et al.. Safety and efficacy of melatonin, clonazepam, and trazodone in patients with Parkinson's disease and sleep disorders: a randomized, double-blind trial. Neurol Sci. 2022, 43:6141-8. 10.1007\/s10072-022-06188-4","journal-title":"Neurol Sci"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110485","article-title":"Effect of melatonin administration on the PER1 and BMAL1 clock genes in patients with Parkinson's disease","volume":"129","author":"Delgado-Lara DL","year":"2020","unstructured":"Delgado-Lara DL, Gonz\u00e1lez-Enr\u00edquez GV, Torres-Mendoza BM, et al.. Effect of melatonin administration on the PER1 and BMAL1 clock genes in patients with Parkinson's disease. Biomed Pharmacother. 2020, 129:110485. 10.1016\/j.biopha.2020.110485","journal-title":"Biomed Pharmacother"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3390\/neurolint15010031","article-title":"Chronic administration of melatonin: physiological and clinical considerations","volume":"15","author":"Givler D","year":"2023","unstructured":"Givler D, Givler A, Luther PM, et al.. Chronic administration of melatonin: physiological and clinical considerations. Neurol Int. 2023, 15:518-33. 10.3390\/neurolint15010031","journal-title":"Neurol Int"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-079X.2007.00499.x","article-title":"Oral melatonin reduces blood coagulation activity: a placebo-controlled study in healthy young men","volume":"44","author":"Wirtz PH","year":"2008","unstructured":"Wirtz PH, Spillmann M, B\u00e4rtschi C, Ehlert U, von K\u00e4nel R. Oral melatonin reduces blood coagulation activity: a placebo-controlled study in healthy young men. J Pineal Res. 2008, 44:127-33. 10.1111\/j.1600-079X.2007.00499.x","journal-title":"J Pineal Res"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1123\/japa.2017-0312","article-title":"Melatonin affects postural control in community-dwelling older adults while dual tasking: a randomized observation study","author":"Lui MF","year":"2018","unstructured":"Lui MF, Chow HK, Wong WM, Tsang WN. Melatonin affects postural control in community-dwelling older adults while dual tasking: a randomized observation study. J Aging Phys Act. 2018, 1-6. 10.1123\/japa.2017-0312","journal-title":"J Aging Phys Act"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1002\/hup.980","article-title":"Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers","volume":"23","author":"Otmani S","year":"2008","unstructured":"Otmani S, Demazi\u00e8res A, Staner C, Jacob N, Nir T, Zisapel N, Staner L. Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum Psychopharmacol. 2008, 23:693-705. 10.1002\/hup.980","journal-title":"Hum Psychopharmacol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2022.11142","article-title":"Benefits and adverse events of melatonin use in the elderly (review)","volume":"23","author":"Anghel L","year":"2022","unstructured":"Anghel L, Baroiu L, Popazu CR, et al.. Benefits and adverse events of melatonin use in the elderly (review). Exp Ther Med. 2022, 23:219. 10.3892\/etm.2022.11142","journal-title":"Exp Ther Med"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-079x.1998.tb00396.x","article-title":"Monozygotic twins with Alzheimer's disease treated with melatonin: case report","volume":"25","author":"Brusco LI","year":"1998","unstructured":"Brusco LI, M\u00e1rquez M, Cardinali DP. Monozygotic twins with Alzheimer's disease treated with melatonin: case report. J Pineal Res. 1998, 25:260-3. 10.1111\/j.1600-079x.1998.tb00396.x","journal-title":"J Pineal Res"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13229","article-title":"Pharmacological and non-pharmacological interventions to enhance sleep in mild cognitive impairment and mild Alzheimer's disease: a systematic review","volume":"30","author":"Blackman J","year":"2021","unstructured":"Blackman J, Swirski M, Clynes J, Harding S, Leng Y, Coulthard E. Pharmacological and non-pharmacological interventions to enhance sleep in mild cognitive impairment and mild Alzheimer's disease: a systematic review. J Sleep Res. 2021, 30:e13229. 10.1111\/jsr.13229","journal-title":"J Sleep Res"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1111\/jpi.12774","article-title":"Melatonin ameliorates cognitive deficits through improving mitophagy in a mouse model of Alzheimer's disease","volume":"71","author":"Chen C","year":"2021","unstructured":"Chen C, Yang C, Wang J, et al.. Melatonin ameliorates cognitive deficits through improving mitophagy in a mouse model of Alzheimer's disease. J Pineal Res. 2021, 71:e12774. 10.1111\/jpi.12774","journal-title":"J Pineal Res"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ibneur.2023.01.005","article-title":"Melatonin reduces \u03b2-amyloid accumulation and improves short-term memory in streptozotocin-induced sporadic Alzheimer's disease model","volume":"14","author":"Andrade MK","year":"2023","unstructured":"Andrade MK, Souza LC, Azevedo EM, Bail EL, Zanata SM, Andreatini R, Vital MA. Melatonin reduces \u03b2-amyloid accumulation and improves short-term memory in streptozotocin-induced sporadic Alzheimer's disease model. IBRO Neurosci Rep. 2023, 14:264-72. 10.1016\/j.ibneur.2023.01.005","journal-title":"IBRO Neurosci Rep"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.784314","article-title":"Melatonin treatment for sleep disorders in Parkinson's disease: a meta-analysis and systematic review","volume":"14","author":"Ma H","year":"2022","unstructured":"Ma H, Yan J, Sun W, Jiang M, Zhang Y. Melatonin treatment for sleep disorders in Parkinson's disease: a meta-analysis and systematic review. Front Aging Neurosci. 2022, 14:784314. 10.3389\/fnagi.2022.784314","journal-title":"Front Aging Neurosci"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2020.105878","article-title":"Melatonin supplementation and the effects on clinical and metabolic status in Parkinson's disease: a randomized, double-blind, placebo-controlled trial","volume":"195","author":"Daneshvar Kakhaki R","year":"2020","unstructured":"Daneshvar Kakhaki R, Ostadmohammadi V, Kouchaki E, et al.. Melatonin supplementation and the effects on clinical and metabolic status in Parkinson's disease: a randomized, double-blind, placebo-controlled trial. Clin Neurol Neurosurg. 2020, 195:105878. 10.1016\/j.clineuro.2020.105878","journal-title":"Clin Neurol Neurosurg"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2020.03.029","article-title":"Prolonged-release melatonin in Parkinson's disease patients with a poor sleep quality: a randomized trial","volume":"75","author":"Ahn JH","year":"2020","unstructured":"Ahn JH, Kim M, Park S, et al.. Prolonged-release melatonin in Parkinson's disease patients with a poor sleep quality: a randomized trial. Parkinsonism Relat Disord. 2020, 75:50-4. 10.1016\/j.parkreldis.2020.03.029","journal-title":"Parkinsonism Relat Disord"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5577541","article-title":"Effect of melatonin administration on mitochondrial activity and oxidative stress markers in patients with Parkinson's disease","volume":"2021","author":"Jim\u00e9nez-Delgado A","year":"2021","unstructured":"Jim\u00e9nez-Delgado A, Ortiz GG, Delgado-Lara DL, et al.. Effect of melatonin administration on mitochondrial activity and oxidative stress markers in patients with Parkinson's disease. Oxid Med Cell Longev. 2021, 2021:5577541. 10.1155\/2021\/5577541","journal-title":"Oxid Med Cell Longev"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-022-00352-5","article-title":"Melatonin ameliorates Parkinson's disease via regulating microglia polarization in a ROR\u03b1-dependent pathway","volume":"8","author":"Li J","year":"2022","unstructured":"Li J, Liu H, Wang X, et al.. Melatonin ameliorates Parkinson's disease via regulating microglia polarization in a ROR\u03b1-dependent pathway. NPJ Parkinsons Dis. 2022, 8:90. 10.1038\/s41531-022-00352-5","journal-title":"NPJ Parkinsons Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/205309-neuroprotective-potential-of-melatonin-evaluating-therapeutic-efficacy-in-alzheimers-and-parkinsons-diseases","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:12:12Z","timestamp":1707509532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/205309-neuroprotective-potential-of-melatonin-evaluating-therapeutic-efficacy-in-alzheimers-and-parkinsons-diseases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":55,"URL":"https:\/\/doi.org\/10.7759\/cureus.50948","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,22]]}}}